Drug intelligence / Profile preview

Moderna + Comirnaty + Vaxzevria

Development stage: Unknown
Lead developer: Moderna
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

This is a combination of three different COVID-19 vaccines. Moderna (Spikevax) and Comirnaty (Pfizer-BioNTech) are mRNA-based vaccines, while Vaxzevria (AstraZeneca) is a non-replicating viral vector vaccine. All three vaccines are designed to protect against COVID-19 by targeting the spike protein of SARS-CoV-2. The 2024-2025 formulations have been updated to provide protection against circulating strains of the virus. This query refers to three distinct vaccines and not a single combination product.

Other names: SpikevaxPfizer-BioNTech COVID-19 vaccine

Targets

SARS-CoV-2 spike

Beyond the preview

Go deeper on Moderna + Comirnaty + Vaxzevria.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Moderna + Comirnaty + Vaxzevria.

Explore the full profile